Skip to Content
Merck
CN

SML2688

J30-8

≥98% (HPLC)

Synonym(s):

(5Z)-2-(2-Chlorophenylimino)-5-(5-fluoro-2-oxoindolin-3-ylidene)thiazolidin-4-one, 2-((2-Chlorophenyl)imino)-5-((Z)-5-fluoro-2-oxoindolin-3-ylidene)thiazolidin-4-one

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H9ClFN3O2S
CAS Number:
2366255-71-0
Molecular Weight:
373.79
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD05026464

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

Fc1cc2c(cc1)NC(=O)\C\2=C3/SC(=NC/3=O)Nc4c(cccc4)Cl

InChI

1S/C17H9ClFN3O2S/c18-10-3-1-2-4-12(10)21-17-22-16(24)14(25-17)13-9-7-8(19)5-6-11(9)20-15(13)23/h1-7H,(H,20,23)(H,21,22,24)/b14-13-

InChI key

HNOFQKYBQYGFNQ-YPKPFQOOSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

J30-8 is a potent c-Jun N-terminal kinase JNK3 subtype-selective inhibtior (human JNK3 IC50 = 40 nM, JNK1α1 & JNK2α2 IC50 >100 μM) that exhibits excellent kinome-wide selectivity (IC50 >7.7 μM against 398 kinase targets) and neuroprotective efficacy against Aβ25-35 toxicity in SH-SY5Y cultures (1 μM). When compared with the pan-JNK inhibitor SP600125 in the APPswe/PS1dE9 murine AD model in vivo (30 mg/kg ip.), J30-8 offers superior therapeutic efficacy and pharmacokinetic properties with longer retention time (elimination t1/2 = 16.11 vs 1.23 hrs; plasma conc = 41 ng/mL vs 22 ng/mL 24 hr post ip.) and greater brain-permeability (brain/plasma ratio = 0.40 vs. 0.14 8 hr post ip.).
Potent JNK3 subtype-selective c-Jun N-terminal kinase inhibtior with superior in vivo efficacy, pharmacokinetics and brain-permeability in AD mice than SP600125.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000093062
0000093340
0000079400

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xiaodong Dou et al.
Journal of medicinal chemistry, 62(14), 6645-6664 (2019-07-04)
Alzheimer's disease (AD) is one of the most challenging diseases around the world with no effective clinical treatment. Previous studies have suggested c-Jun N-terminal kinase 3 (JNK3) as an attractive therapeutic target for AD. Herein, we report 3-substituted indolin-2-one derivatives

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service